Faslodex Seen to Ably Treat Advanced and Hormone Receptor-Positive Breast Cancers

Faslodex Seen to Ably Treat Advanced and Hormone Receptor-Positive Breast Cancers
Women with locally advanced or metastatic hormone receptor-positive breast cancer may strongly benefit from treatment with the estrogen receptor degrader Faslodex (fulvestrant), according to the results of a Phase 3 study. The findings, recently presented at the European Society for Medical oncology (ESMO) Congress, held Oct. 7–11 in Denmark, reveal that Faslodex improves progression-free survival

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *